Prognostic value of platelet to lymphocyte ratio in predicting survival of patients with metastatic castration‐resistant prostate cancer receiving abiraterone acetate: An evidence‐based case report and review of literature
- Resource Type
- Authors
- Ilonka Amaia; Addina W. Moekti; Rifqha Aulina; Raksheeth Agarwal; Oliver Emmanuel Yausep; Anthony Eka Wijaya; Ikhwan Rinaldi; Agus Rizal Ardy Hariandy Hamid
- Source
- Clinical Case Reports
Clinical Case Reports, Vol 7, Iss 8, Pp 1585-1590 (2019)
- Subject
- Oncology
medicine.medical_specialty
Evidence-based practice
Lymphocyte
lcsh:Medicine
Case Report
Case Reports
lymphocyte
030204 cardiovascular system & hematology
Castration resistant
03 medical and health sciences
Prostate cancer
chemistry.chemical_compound
0302 clinical medicine
abiraterone
Internal medicine
medicine
Platelet
platelet
lcsh:R5-920
metastatic Castration‐Resistant Prostate Cancer
business.industry
platelet to lymphocyte ratio
lcsh:R
Abiraterone acetate
General Medicine
prostate cancer
medicine.disease
body regions
Abiraterone
medicine.anatomical_structure
chemistry
030220 oncology & carcinogenesis
Cutoff point
lcsh:Medicine (General)
business
- Language
- ISSN
- 2050-0904
Platelet to lymphocyte ratio (PLR) is a candidate prognostic marker for metastatic castration‐resistant prostate cancer patients receiving abiraterone acetate and evidence demonstrates that a high PLR is associated with poor survival. More studies are required to verify current findings and establish a definite cutoff point.